Precision Medicine in Oncology® | Specialty

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

Baselga Recaps Research Into Three Breast Cancer Pathways

April 9th 2013

José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.

AACR Rally Protests Cuts to NIH Budget

April 8th 2013

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

OncLive Collaborates With Renowned Cancer Centers

April 2nd 2013

Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive's Strategic Alliance Partnership Program.

(Molecular) Pathways, Pathways, and More Pathways

April 2nd 2013

The oncology we all learned over the past three decades will soon be a thing of the past, making way for therapy decisions based on what molecular switches should be turned on and off, and of equal importance, in what sequence.

Dr. Andre on Research in Metastatic Breast Cancer

April 2nd 2013

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Dr. Jennifer Brown on Mutations and Targets in CLL

April 1st 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia.

Imatinib Therapy Matures: GIST Research Sheds Light on Mutations, Drug Levels

March 26th 2013

Recently reported data demonstrate that the presence of a specific mutation in PDGFRA predicts for the lack of activity for the imatinib in patients with gastrointestinal stromal tumors.

BCR Inhibitors Show Promise in Treating Chronic Lymphocytic Leukemia

March 25th 2013

Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.

Emanuel Petricoin on Genomic Profiling and Targeted Therapy

March 22nd 2013

Emanuel "Chip" Petricoin III, PhD, from George Mason University, discusses the inability of DNA and RNA profiling to predict response to treatment with targeted therapies.

Dr. Cheson on Novel ADCs in Non-Hodgkin Lymphoma

March 20th 2013

Bruce D. Cheson, MD, from Georgetown Lombardi Comprehensive Cancer Center, discusses the prospect of using antibody drug conjugates in non-Hodgkin lymphomas, including follicular lymphoma.

Managing NETs in the Community Setting

March 14th 2013

Treating Neuroendocrine Tumors With Chemotherapy

March 14th 2013

Targeted Therapies in Neuroendocrine Tumors

March 14th 2013

Emerging Treatment Options in Neuroendocrine Tumors

March 14th 2013

Role of Somatostatin Analogs in Neuroendocrine Tumors

March 14th 2013

Surgical Treatment of Neuroendocrine Tumors

March 14th 2013

The Genetics Behind Familial Neuroendocrine Tumors

March 14th 2013

Techniques for Diagnosing Neuroendocrine Tumors

March 14th 2013

Challenges in the Diagnosis of Neuroendocrine Tumors

March 14th 2013